| Not Yet Recruiting | A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+ NCT07310420 | TerSera Therapeutics LLC | Phase 1 |
| Not Yet Recruiting | Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With A NCT07427394 | AstraZeneca | Phase 2 |
| Not Yet Recruiting | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322 | Regor Pharmaceuticals Inc. | Phase 1 |
| Recruiting | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer NCT07408089 | Boundless Bio, Inc. | Phase 1 |
| Not Yet Recruiting | Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary In NCT07406789 | TNC Nutrición Terapéutica S.L. | Phase 2 |
| Not Yet Recruiting | A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer NCT07227831 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumor NCT07318805 | Pfizer | Phase 1 |
| Recruiting | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Stan NCT07281833 | West German Study Group | Phase 3 |
| Recruiting | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers NCT07259226 | UNICANCER | Phase 2 |
| Completed | Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases NCT07225790 | Brigham and Women's Hospital | — |
| Not Yet Recruiting | SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer NCT07125950 | Henan Cancer Hospital | Phase 2 |
| Recruiting | A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant S NCT07130383 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 |
| Recruiting | Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160 | Wenjin Yin | Phase 2 |
| Completed | Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases NCT07274709 | Shirley Vichy Wang | — |
| Not Yet Recruiting | A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer NCT07173556 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Trastuzumab Deruxtecan in Advanced Breast Cancer NCT07180264 | Wenjin Yin | — |
| Recruiting | Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer NCT07180082 | Wenjin Yin | Phase 2 |
| Recruiting | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Met NCT06982521 | Relay Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | Acceptability and Feasibility of PSC Model of Serious Illness Communication NCT07428655 | National Cancer Centre, Singapore | N/A |
| Recruiting | Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-L NCT07037199 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer NCT07083505 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Recruiting | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors NCT06997029 | Bristol-Myers Squibb | Phase 1 |
| Active Not Recruiting | Emulation of the PALOMA-2 Trial NCT07178743 | Brigham and Women's Hospital | — |
| Recruiting | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursin NCT07405931 | Ulsan University Hospital | N/A |
| Recruiting | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow A NCT06486883 | MedSIR | Phase 2 |
| Not Yet Recruiting | Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer NCT07041437 | Fudan University | Phase 2 |
| Recruiting | Engage Psychosocial Intervention for Cancer Symptoms NCT06555588 | Duke University | N/A |
| Recruiting | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors NCT06993844 | Ensem Therapeutics | Phase 1 / Phase 2 |
| Recruiting | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors NCT06769425 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Adva NCT06941142 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Recruiting | Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in S NCT06710990 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Active Not Recruiting | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast NCT06612203 | MedSIR | Phase 1 / Phase 2 |
| Not Yet Recruiting | Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast NCT06750848 | Jundong Wu | Phase 2 |
| Recruiting | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. NCT06382948 | MedSIR | Phase 3 |
| Not Yet Recruiting | Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer NCT06470672 | Fudan University | Phase 2 |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer NCT06638307 | Stemline Therapeutics, Inc. | Phase 1 |
| Recruiting | Study of DM5167 in Patients With Advanced Solid Tumors NCT07101601 | DIGMBIO | Phase 1 |
| Recruiting | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 | Fudan University | Phase 2 |
| Recruiting | Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 | Guangdong Provincial People's Hospital | Phase 2 |
| Recruiting | A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensi NCT06776861 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Recruiting | To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatmen NCT06500494 | Pierre Fabre Medicament | — |
| Recruiting | Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormo NCT06123988 | University of Miami | N/A |
| Recruiting | The COMPASSION Study NCT06507930 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequentia NCT06656624 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer NCT06548919 | SciClone Pharmaceuticals | — |
| Recruiting | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestra NCT06380751 | AstraZeneca | Phase 3 |
| Active Not Recruiting | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer NCT06590857 | RayzeBio, Inc. | Phase 1 / Phase 2 |
| Recruiting | Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC NCT06544577 | SciClone Pharmaceuticals | — |
| Recruiting | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC NCT06263543 | Reshma L. Mahtani, D.O. | Phase 2 |
| Not Yet Recruiting | Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer NCT06433609 | Beijing GoBroad Hospital | Phase 2 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Dalpiciclib in HR+/HER2- ABC NCT06301438 | RenJi Hospital | — |
| Not Yet Recruiting | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer NCT06339281 | Li Huiping | Phase 2 |
| Enrolling By Invitation | Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC NCT07359404 | YING FAN | Phase 2 |
| Recruiting | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Old NCT06044623 | Region Örebro County | Phase 3 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 NCT06354114 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monothe NCT06298084 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 / Phase 2 |
| Unknown | Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) NCT06724835 | Shenzhen Celconta Life Science Co., Ltd. | Phase 1 |
| Recruiting | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer NCT06447623 | Fudan University | Phase 3 |
| Unknown | HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer NCT06328387 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequentia NCT06375707 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treate NCT06217185 | Hebei Medical University Fourth Hospital | Phase 4 |
| Not Yet Recruiting | TIL Therapy for Patients With Advanced Solid Tumors NCT06107894 | NeogenTC | Phase 1 |
| Recruiting | Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for H NCT06176534 | Henan Cancer Hospital | Phase 2 |
| Unknown | Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 I NCT06338605 | Erasmus Medical Center | — |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283 | BeOne Medicines | Phase 1 |
| Recruiting | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer NCT06016738 | Olema Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Whole Body MRI in Oncology NCT06895291 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Withdrawn | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer NCT05655598 | Brown University | Phase 1 |
| Recruiting | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast C NCT05949541 | Fudan University | Phase 2 |
| Recruiting | Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or H NCT06125834 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer NCT05876065 | Wenjin Yin | N/A |
| Active Not Recruiting | PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin NCT05810870 | MedSIR | Phase 2 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Recruiting | Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) NCT05861830 | Peking Union Medical College Hospital | Phase 3 |
| Recruiting | RC48-ADC in HER2-low Advanced Breast Cancer NCT05831878 | RenJi Hospital | N/A |
| Unknown | A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Comp NCT05753865 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors NCT05759949 | Relay Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-D NCT05323955 | Carey Anders, M.D. | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of NCT05383170 | Cytovation AS | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced NCT05654623 | Pfizer | Phase 3 |
| Unknown | A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer NCT05775575 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer NCT05893368 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Withdrawn | Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer NCT04756765 | Stanford University | Phase 2 |
| Recruiting | Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor NCT05536128 | Seoul National University Hospital | Phase 2 |
| Recruiting | SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095 | Fudan University | Phase 2 |
| Active Not Recruiting | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Su NCT04920708 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | Rehabilitation for People With Advanced Cancer NCT05424068 | University Health Network, Toronto | N/A |
| Completed | Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects NCT06290466 | Ahon Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Ad NCT05452213 | Institut fuer Frauengesundheit | Phase 4 |
| Withdrawn | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC NCT05191004 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Unknown | Dalpiciclib Plus Letrozole and Capecitabine NCT05469750 | Fujian Medical University Union Hospital | Phase 2 |
| Completed | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, H NCT05631795 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) NCT06525675 | MedSIR | — |
| Suspended | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing A NCT05076591 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Not Yet Recruiting | The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast C NCT05431504 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Terminated | A Study in Patients With Advanced Breast Cancer NCT04942054 | Sun Pharma Advanced Research Company Limited | Phase 1 |
| Completed | Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer NCT06098599 | Luye Pharma Group Ltd. | Phase 1 |
| Withdrawn | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer NCT05227131 | MedSIR | Phase 2 |
| Terminated | A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer NCT04655573 | Duke University | — |
| Unknown | A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer NCT05274893 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Withdrawn | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer NCT04826016 | MedSIR | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer NCT05257395 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 |
| Terminated | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific NCT04862143 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Ef NCT05439499 | Ahon Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer NCT05255523 | Fujian Medical University Union Hospital | Phase 2 |
| Active Not Recruiting | RCT of CBD for Anxiety in Advanced Breast Cancer NCT04482244 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Ef NCT05438810 | Ahon Pharmaceutical Co., Ltd. | Phase 3 |
| Terminated | A Study of Lerociclib in Participants With Advanced Breast Cancer NCT05085002 | EQRx, Inc. | Phase 2 |
| Recruiting | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance NCT05216432 | Relay Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of GC101 TIL in Advanced Breast Cancer (10hospital) NCT05142475 | Shanghai Juncell Therapeutics | EARLY_Phase 1 |
| Active Not Recruiting | A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer NCT05077449 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 |
| Withdrawn | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast NCT04316169 | Medical College of Wisconsin | Phase 1 |
| Unknown | Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap NCT05156619 | Hadassah Medical Organization | — |
| Completed | Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer NCT05173103 | University of Milano Bicocca | — |
| Active Not Recruiting | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated NCT05063786 | Spanish Breast Cancer Research Group | Phase 3 |
| Unknown | PFMT Educational Intervention for Patients With Advancer Breast Cancer NCT04953377 | Onkologikoa | N/A |
| Unknown | Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab a NCT05020964 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced B NCT05047848 | Liaoning Cancer Hospital & Institute | N/A |
| Unknown | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic NCT04924699 | Shanghai Miracogen Inc. | Phase 2 / Phase 3 |
| Unknown | A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer NCT05337657 | Genor Biopharma Co., Ltd. | Phase 1 |
| Completed | Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance NCT04728035 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. NCT04733417 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency NCT04892693 | Seoul National University Hospital | Phase 2 |
| Recruiting | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Terminated | CB-103 Plus NSAI In Luminal Advanced Breast Cancer NCT04714619 | MedSIR | Phase 2 |
| Unknown | Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- A NCT04856371 | Haihe Biopharma Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postm NCT04524000 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Recruiting | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413 | National Cancer Institute (NCI) | Phase 1 |
| Completed | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Br NCT03685331 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC NCT04408118 | MedSIR | Phase 2 |
| Active Not Recruiting | Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer NCT04653740 | Centre Oscar Lambret | N/A |
| Completed | Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer NCT04436393 | Guardant Health, Inc. | — |
| Completed | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease NCT04420598 | MedSIR | Phase 2 |
| Unknown | Implementing Patients´ Competence in Oral Breast Cancer Therapy NCT04030728 | Onco Medical Consult GmbH | — |
| Recruiting | Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Brea NCT05530057 | Seoul National University Hospital | Phase 2 |
| Terminated | Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) NCT04227327 | University of Milano Bicocca | Phase 2 |
| Completed | A Phase I Study of LX-039 Tablets NCT04097756 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer NCT04188548 | Eli Lilly and Company | Phase 1 |
| Recruiting | FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (R NCT06193525 | Erasmus Medical Center | Phase 2 |
| Unknown | Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients NCT04456855 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Unknown | A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative NCT03966898 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Phase I Study of BEBT-209 in Women With Advanced Breast Cancer NCT06047184 | BeBetter Med Inc | Phase 1 |
| Unknown | A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Bre NCT03927456 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treat NCT04004910 | Immunicom Inc | Phase 1 / Phase 2 |
| Withdrawn | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer NCT03524261 | Fuda Cancer Hospital, Guangzhou | Phase 2 |
| Completed | A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics NCT03850873 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer NCT05812326 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 / Phase 2 |
| Terminated | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer NCT03931551 | MedSIR | Phase 2 |
| Completed | Safety and Pharmacokinetics of ODM-209 NCT03878823 | Orion Corporation, Orion Pharma | Phase 1 / Phase 2 |
| Completed | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) NCT03809988 | MedSIR | Phase 2 |
| Withdrawn | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously NCT03811418 | iOMEDICO AG | Phase 3 |
| Recruiting | Plasmodium Immunotherapy for Breast and Liver Cancers NCT03474822 | CAS Lamvac Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cance NCT03829306 | Spanish Breast Cancer Research Group | — |
| Active Not Recruiting | A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors NCT04539496 | Sihuan Pharmaceutical Holdings Group Ltd. | Phase 1 / Phase 2 |
| Unknown | Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally NCT03538171 | Taizhou EOC Pharma Co., Ltd. | Phase 3 |
| Completed | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast C NCT03455270 | G1 Therapeutics, Inc. | Phase 1 |
| Completed | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive an NCT03481998 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Hypo-Fractionated Radiotherapy in Breast Cancer NCT03669497 | Tata Medical Center | N/A |
| Completed | Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer NCT03405168 | Sun Yat-sen University | Phase 2 |
| Completed | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breas NCT03205761 | Spanish Breast Cancer Research Group | Phase 2 |
| Completed | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally NCT03312738 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Bioinformation Therapy for Breast Cancer NCT03240224 | Fuda Cancer Hospital, Guangzhou | Phase 2 / Phase 3 |
| Completed | Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC NCT03025880 | Spanish Breast Cancer Research Group | Phase 2 |
| Unknown | A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors NCT03125746 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Phase 1 |
| Unknown | Clinical Study of Decitabine and Paclitaxel Combination Therapy NCT03282825 | Dong Wha Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer NCT03072992 | National Center of Oncology, Armenia | Phase 2 |
| Unknown | Metronomic PLD in Patients With Primary Endocrine Resistant ABC NCT03071926 | Fudan University | Phase 2 |
| Completed | Palbociclib in Real World Practice NCT03280303 | Pfizer | — |
| Completed | A Study of RC48-ADC in Subjects With Advanced Breast Cancer NCT03052634 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) NCT03182634 | Institute of Cancer Research, United Kingdom | Phase 2 |
| Active Not Recruiting | Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer NCT06926088 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 NCT02952729 | Mersana Therapeutics | Phase 1 |
| Completed | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer NCT02657889 | Tesaro, Inc. | Phase 1 / Phase 2 |
| Unknown | A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast NCT03047889 | Chinese Academy of Medical Sciences | — |
| Completed | A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer NCT02599363 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cance NCT02499146 | Pfizer | Phase 1 |
| Completed | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors NCT02401347 | Melinda Telli | Phase 2 |
| Completed | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) NCT02580448 | Innocrin Pharmaceutical | Phase 1 / Phase 2 |
| Completed | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. NCT02422615 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Cambridge Brain Mets Trial 1 NCT02768337 | Cambridge University Hospitals NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | Patterns of Prescribing and Monitoring of Palbociclib NCT03285568 | Rush University Medical Center | — |
| Completed | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Gr NCT02091960 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Completed | Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) NCT02027376 | Spanish Breast Cancer Research Group | Phase 1 |
| Completed | Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women Wi NCT02069093 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Halaven Patient Registry (Metastatic Breast Cancer, MBC) NCT03245112 | Chang Gung Memorial Hospital | — |
| Completed | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mu NCT01989546 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) NCT01976169 | University of Texas Southwestern Medical Center | Phase 1 |
| Terminated | Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With A NCT01836640 | Dartmouth-Hitchcock Medical Center | — |
| Completed | Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer NCT01876238 | Case Comprehensive Cancer Center | N/A |
| Unknown | A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer NCT01931943 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer P NCT04304352 | European Institute of Oncology | Phase 2 |
| Unknown | Level of HER2-neu Gene Amplification an Response to Trastuzumab NCT00874146 | Istituto Clinico Humanitas | — |
| Unknown | A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solven NCT00915369 | Fresenius Kabi Oncology Ltd. | Phase 1 |
| Completed | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer NCT00777101 | Puma Biotechnology, Inc. | Phase 2 |
| Terminated | Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Can NCT00793546 | Pfizer | Phase 2 |
| Unknown | The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advance NCT01311037 | King Faisal Specialist Hospital & Research Center | — |
| Completed | HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breas NCT00719875 | Yale University | Phase 1 |
| Completed | Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Rec NCT00754325 | Bristol-Myers Squibb | Phase 2 |
| Unknown | A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patien NCT00717951 | Academy Military Medical Science, China | Phase 2 |
| Terminated | Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression NCT00522457 | Neovii Biotech | Phase 2 |
| Completed | Phase II Dasatinib Study in Advanced Breast Cancer NCT00546104 | Duke University | Phase 2 |
| Completed | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors NCT00445458 | Puma Biotechnology, Inc. | Phase 1 / Phase 2 |
| Terminated | Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer NCT00496366 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. NCT00428220 | Pfizer | N/A |
| Completed | Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer NCT00452673 | Bristol-Myers Squibb | Phase 1 |
| Completed | Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cance NCT00561119 | Samsung Medical Center | Phase 3 |
| Completed | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced NCT00398567 | Puma Biotechnology, Inc. | Phase 1 / Phase 2 |
| Completed | AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. NCT00454805 | AstraZeneca | Phase 2 |
| Terminated | Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After NCT00452140 | Neovii Biotech | Phase 2 |
| Recruiting | Southeast Netherlands Advanced Metastatic Breast Cancer Registry NCT03577197 | Academisch Ziekenhuis Maastricht | — |
| Completed | Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer NCT00562458 | AstraZeneca | — |
| Completed | Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Canc NCT00387907 | Sanofi | Phase 2 |
| Terminated | A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Can NCT02054338 | Pierre Fabre Medicament | Phase 3 |
| Completed | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen a NCT00313170 | AstraZeneca | Phase 2 |
| Completed | Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal NCT00322348 | AstraZeneca | Phase 2 |
| Completed | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) NCT00305448 | AstraZeneca | Phase 2 |
| Completed | E3 Breast Cancer Taxotere Combination NCT00494481 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Faslodex Advanced Breast Cancer Local Chinese Study NCT00327769 | AstraZeneca | Phase 3 |
| Completed | A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) NCT00106145 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Faslodex 500mg Multiple Dose Tolerability Study in BC Patients NCT00328120 | AstraZeneca | Phase 1 |
| Completed | Second Line Breast Cancer Trial NCT00635713 | AstraZeneca | Phase 3 |